Investor Relations

Press Releases

NanoString Technologies Increases Multiplexing Capacity for Gene Expression Analysis

NanoString Technologies Increases Multiplexing Capacity for Gene Expression Analysis


Researchers can now directly profile up to 800 transcripts in a single tube

SEATTLE, Wash | July 14, 2010   -  NanoString Technologies, Inc., a privately held life sciences company marketing a novel digital molecular barcoding technology for detecting and counting large sets of targets in biological samples, today announced that it has increased the throughput of its nCounter® Analysis System by expanding its multiplexing capacity to 800 gene transcripts per reaction.  This additional capability allows for the high-resolution analysis of 250 additional targets from the same amount of sample, thereby increasing the efficiency of experiments and enabling researchers to perform studies not feasible using other technologies.

With a growing interest in evaluating complex cellular interactions across large numbers of biological samples, scientists are seeking solutions capable of efficiently analyzing defined sets of targets at very high resolution.  The nCounter Analysis System is meeting this need by providing a simple workflow, multiplexing, and direct detection and counting of individual RNA transcripts.  The application of this technology to elucidate complex biological systems in cancer, developmental biology and cell signaling is demonstrated in a series of recent journal publications (for more information see:

“One of the important reasons customers choose the nCounter Analysis System is that it provides gold-standard molecular quantification in a highly multiplexed format, and it is easier to use than other technology platforms,” said Brad Gray, President and CEO, NanoString Technologies.  “With the new multiplexing capacity, it’s as though you are performing 800 qPCR reactions in a single tube with only four pipetting steps.”

The nCounter Analysis System is widely used for gene signature validation, translational research, pathway analysis, and validation of microarray and next-generation sequencing.  It includes a fully automated Prep Station, a Digital Analyzer, the CodeSet (molecular barcodes) and all reagents needed to perform the analysis.  The nCounter System offer protocols starting with as little as 100ng of material from a variety of specimen types including FFPE samples, cell lysate, whole-blood lysate, and total RNA.  In addition to solutions for gene expression analysis, custom and off-the-shelf assay panels are available for miRNA profiling and genomic copy number variation detection.  More information is available at

About NanoString Technologies, Inc.
NanoString Technologies is a privately held life sciences company marketing a complete solution for detecting and counting large sets of target molecules in biological samples. The company’s nCounter® Analysis System is the first and only technology platform to deliver highly multiplexed, direct profiling of individual molecules in a single reaction without amplification. The nCounter Analysis System offers a cost-effective way to easily profile hundreds of gene transcripts, copy number variations, or miRNAs simultaneously with high sensitivity and precision. The company’s technology enables a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. NanoString is also developing the technology for use in molecular diagnostics.